Skip to content

Merck Keytruda Combo Reduced Risk of Death in Some Esophageal Cancers

September 21, 2020

Merck & Co. Inc. on Monday said data from a Phase 3 trial of Keytruda in combination with platinum-based chemotherapy showed the treatment led to a reduced risk of death in certain esophageal cancer patients.

The company said its KEYNOTE-590 trial was evaluating Keytruda in combination with platinum-based chemotherapy as a “first-line treatment of patients with locally advanced or metastatic esophageal and gastroesophageal junction cancer.”

According to Merck, “Keytruda plus chemotherapy demonstrated superior overall survival and progression-free survival versus chemotherapy in these patients regardless of PD-l1 expression status and tumor histology.” Merck also said, “Keytruda in combination with chemotherapy significantly improved overall survival, reducing the risk of death by 27% versus chemotherapy in all randomized patients.”

The data were presented at the European Society for Medical Oncology Virtual Congress 2020 on Sept. 21, Merck said.

Merck added that it will be sharing the data with regulatory authorities worldwide.

https://www.marketscreener.com/quote/stock/MERCK-CO-INC-13611/news/Merck-Keytruda-in-Combination-Reduced-Risk-of-Death-in-Certain-Esophageal-Cancer-Patients-31333280/

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: